Spark Therapeutics

What's taking the FTC so long? Roche won't say, but insists it will bag Spark on time — despite third delay
What's taking the FTC so long? Roche won't say, but insists it will bag Spark on time — despite third delay
Endpoints
Roche
Spark Therapeutics
M&A
Flag link:
Roche delays $4.3B Spark buyout — again — as FTC review drags on
Roche delays $4.3B Spark buyout — again — as FTC review drags on
Endpoints
Roche
Spark Therapeutics
M&A
FTC
Flag link:
Roche must ask Spark shareholders once again to sell
Roche must ask Spark shareholders once again to sell
Biopharma Dive
Roche
Spark Therapeutics
gene therapy
M&A
Flag link:
Gene therapy progress spurs competition in biotech buyouts
Gene therapy progress spurs competition in biotech buyouts
Biopharma Dive
biotech
gene therapy
M&A
Biogen
Nightstar Therapeutics
Roche
Spark Therapeutics
Flag link:
Spark bidding war drove Roche bid up by $2.1 billion
Spark bidding war drove Roche bid up by $2.1 billion
BioCentury
Spark Therapeutics
Roche
M&A
Flag link:
Roche Bets $4.8B on Spark Therapeutics and the Future of Gene Therapy
Roche Bets $4.8B on Spark Therapeutics and the Future of Gene Therapy
Xconomy
Roche
gene therapy
Spark Therapeutics
M&A
Flag link:
This Gene Therapy Stock Could Soon Hit The Auction Block — Here's Why
This Gene Therapy Stock Could Soon Hit The Auction Block — Here's Why
Investors Business Daily
uniQure
M&A
hemophilia B
AMT-061
Pfizer
Spark Therapeutics
Flag link:
Uniqure turns the screw on Spark and Pfizer
Uniqure turns the screw on Spark and Pfizer
EP Vantage
uniQure
Spark Therapeutics
Pfizer
AMT-061
hemophilia B
Flag link:
JPM19: Spark looks at scale, manufacturing as gene therapy matures
JPM19: Spark looks at scale, manufacturing as gene therapy matures
Biopharma Dive
JPMHC 2019
Spark Therapeutics
gene therapy
Luxturna
Flag link:
2 Sets of Disasters Biotech Will Pay For in 2019
2 Sets of Disasters Biotech Will Pay For in 2019
Yahoo/Motley Fool
Gilead Sciences
Yescarta
Novartis
Kymriah
Spark Therapeutics
Luxturna
Flag link:
Luxturna cleared for sale in Europe, but payer support uncertain
Luxturna cleared for sale in Europe, but payer support uncertain
Biopharma Dive
Spark Therapeutics
Luxturna
Europe
gene therapy
Flag link:
Novartis/Spark’s sight gene therapy approved in EU
Novartis/Spark’s sight gene therapy approved in EU
Pharmaforum
Novartis
Spark Therapeutics
Luxturna
gene therapy
Europe
Flag link:
Spark's CSO is wrapping up animal studies on a gene therapy for Pompe disease as new work in the field sees explosive growth
Spark's CSO is wrapping up animal studies on a gene therapy for Pompe disease as new work in the field sees explosive growth
Endpoints
Spark Therapeutics
Pompe disease
SPK-3006
Flag link:
Spark/Novartis eye gene therapy nears EU market – but at what price?
Spark/Novartis eye gene therapy nears EU market – but at what price?
Pharmaforum
Spark Therapeutics
Novartis
Luxturna
gene therapy
Europe
Flag link:
Express Scripts staking out million-dollar gene therapies
Express Scripts staking out million-dollar gene therapies
Reuters
Express Scripts
PBMs
gene therapies
drug pricing
Biomarin
Bluebird Bio
Spark Therapeutics
Flag link:
What's Next for Spark Therapeutics
What's Next for Spark Therapeutics
Motley Fool
Spark Therapeutics
hemophilia
SPK-8011
Flag link:
3 Beaten-Down Biotech Stocks: Can They Recover?
3 Beaten-Down Biotech Stocks: Can They Recover?
Motley Fool
Idera
Spark Therapeutics
Tesaro
Flag link:
7 companies to watch during Q2 earnings
7 companies to watch during Q2 earnings
Biopharma Dive
earnings
Biogen
Gilead Sciences
Amgen
Celgene
AbbVie
Pfizer
Spark Therapeutics
Flag link:
3 Biotech Stocks With Major Catalysts Incoming
3 Biotech Stocks With Major Catalysts Incoming
Motley Fool
Spark Therapeutics
Zogenix
Progenics Pharmaceuticals
SPK-8011
ZX008
Azedra
FDA
Flag link:
Is biopharma’s first $1.5M therapy now in Phase III?
Is biopharma’s first $1.5M therapy now in Phase III?
Endpoints
drug pricing
gene therapy
Luxturna
Spark Therapeutics
Flag link:

Pages